[Adjuvant BCG immunotherapy in the management of superficial bladder tumors].

The net benefit of BCG immunotherapeutic prophylactic effect on recurrence of superficial bladder tumours was investigated. The BCG treatment group consisted of 121 stage Ta, T1 patients, while the control group, 49 patients, was treated only with transurethral resection. During 3-year follow-up recurrence rate in the control group was 55.

Long-term BCG immune therapy of superficial bladder tumours.

Long-term local BCG treatment of superficial bladder tumours is described and the 5-year results are reviewed. Complications of major significance in the course of immune therapy did not occur, loss due to death was not recorded. PPD skin test failed to furnish extra information regarding the biologic behaviour of the tumour.

[Results of BCG immunotherapy in the management of bladder tumors].

The authors reported their results of BCG immunotherapy in the treatment of the bladder cancer. between 1984-1989 60 superficial and 4 muscle infiltrative bladder tumors were treated. The results of 53 BCG treated superficial bladder cancer group were compared to control groups.

[Repeated yearly BCG treatment in superficial bladder cancer].

The authors report on experiences of treatment for superficial bladder cancer with BCG have achieved during three years. To achieve a permanent recidive prophylaxis the 6 weeks long course was repeated yearly. During the 37-12 months follow up a tumor recurrence have been observed in 10 of 49 patients (20.